DOCSLIB.ORG

ICAR) 2 Daily Schedule

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICAR) 2 Daily Schedule May 21-25, 2017 HILTON ATLANTA Atlanta, GA hosted by the INTERNATIONAL SOCIETY FOR ANTIVIRAL RESEARCH (ISAR) Program AND Abstracts Table of Contents Daily Schedule . 3 Organization . 4 Contributors . 5 Keynotes & Networking . 6 Schedule at a Glance . 7 ISAR Awardees . 10 Women in Science Career Development Award Winners . 14 Speaker Biographies . 15 Program Schedule . 23 Abstracts . 49 Author Index . 132 Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 2 Daily Schedule Sunday, May 21, 2017 › Women in Science Roundtable › Drug Discovery and Development 101 › Welcome and Keynote Address › Opening Reception Monday, May 22, 2017 › Keynote Address › Antiviral Immunity Symposium › Gertrude Elion Memorial Award Lecture › Hepatitis Viruses and Retroviruses › Poster Session 1 Tuesday, May 23, 2017 › Antonin Hol’y Memorial Award Lecture › Emerging Viruses › New Member and First Time Attendee Networking › Career Development Panel Wednesday, May 24, 2017 › Shotgun Oral Presentations › Keynote Address › Emerging Infections Symposium › William Prusoff Young Investigator Award Lecture › Respiratory Viruses › Poster Session 2 › Closing Reception and Banquet Thursday, May 25, 2017 › Medicinal Chemistry › DNA Viruses and Respiratory Viruses Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 3 Organization International Society for Antiviral Research and 30th International Conference on Antiviral Research Officers President José Esté Barcelona, Spain President-Elect Past President Johan Neyts Robert Buckheit, Jr. Leuven, Belgium Frederick, MD, USA Treasurer Secretary Brian Gowen Graciela Andrei Logan, UT, USA Leuven, Belgium Board of Directors Andrea Brancale Jennifer Moffat Mike Bray Cardiff, UK Syracuse, NY, USA Chevy Chase, MD, USA Roger Ptak Rhonda Cardin Kathie Seley-Radtke Frederick, MD, USA Cincinnati, OH, USA Baltimore, MD, USA Program Committee Co-Chairs Mark Prichard and Justin Julander Graciela Andrei Andrea Brancale Chris Meier Tim Block José Esté Johan Neyts Mike Bray Maaike Everts Don Smee Randall Lanier Conference Committee Co-Chairs José Esté and Robert Buckheit, Jr. Graciela Andrei Rhonda Cardin Amy Patick Masanori Baba Phil Furman Roger Ptak Mike Bray Brian Gowen Johan Neyts Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 4 Contributors Confirmed Sponsors as of April 27, 2017 Platinum Gilead Sciences, Inc. Foster City, CA, USA Gold Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies South San Francisco, CA, USA AbbVie Inc. Silver JCR Pharmaceutical Co., Ltd. North Chicago, IL, USA Chimerix Inc. Ashiya, Japan Burroughs Wellcome Fund Durham, NC, USA Southern Research Institute Research Triangle Park, NC, USA Birmingham, AL, USA Bronze ACS Infectious Diseases Elsevier B.V. Oxeltis Washington, DC, USA Amsterdam, The Netherlands Montpellier, France Antiva Biosciences Inc. ImQuest BioSciences Inc. Riboscience LLC South San Francisco, CA, USA Frederick, MD, USA Sunnyvale, CA, USA Center for Drug Design, Institute for Antiviral Research, Toyama Chemical Co., Ltd. University of Minnesota Utah State University Tokyo, Japan Minneapolis, MN, USA Logan, UT, USA XpressBio Frederick, MD, USA The ISAR Presidents’ Fund Jan Balzarini Phillip A. Furman José A. Esté Joseph M. Colacino Douglas D. Richman Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 5 Keynotes & Networking Keynote Addresses Sunday, May 21, 2017 Monday, May 22, 2017 Historical Context and Biological Enigma Impact of Transmitted HIV Phenotype of Rhinovirus C on Host-Virus Interactions Ann C. Palmenberg, PhD and Disease Progression University of Wisconsin-Madison Eric Hunter, PhD Emory University Antivirals at the Interface with Public Health: A Case Study of Polio Wednesday, May 24, 2017 Mark A. Pallansch, PhD Zika Antiviral and Vaccine Development Centers for Disease Control Pei-Yong Shi, PhD and Prevention University of Texas Medical Branch Networking Events Women in Science Roundtable New Member and First Time Sunday, May 21, 2017 Attendee Networking 12:00 PM – 1:45 PM Tuesday, May 22, 2017 CRYSTAL BALLROOM 12:30 PM – 2:00 PM ROOM 204-205 Opening Reception Sunday, May 21, 2017 Career Development Panel 6:30 PM – 8:30 PM Tuesday, May 22, 2017 CRYSTAL BALLROOM 2:00 PM – 3:00 PM ROOM 203 Conference Reception and Banquet Wednesday, May 23, 2017 7:00 PM – 10:00 PM WEST BALLROOM Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 6 Schedule at a Glance Sunday, May 21, 2017 TIME EVENT LOCATION 11:00 AM – 5:00 PM Registration GRAND BALLROOM PRE-FUNCTION 12:00 PM – 1:45 PM Women in Science Roundtable CRYSTAL BALLROOM 2:00 PM – 4:00 PM Drug Discovery and Development 101 WEST BALLROOM 4:00 PM – 4:30 PM Coffee Break GRAND BALLROOM PRE-FUNCTION 4:30 PM – 6:30 PM Welcome/Keynote Address: WEST BALLROOM Ann C. Palmenberg, PhD and Mark A. Pallansch, PhD 6:30 PM – 8:30 PM Opening Reception CRYSTAL BALLROOM Light hors d’oeuvres served Monday, May 22, 2017 TIME EVENT LOCATION 8:00 AM – 5:30 PM Registration GRAND BALLROOM PRE-FUNCTION 8:00 AM – 9:00 AM Continental Breakfast GRAND BALLROOM PRE-FUNCTION 9:00 AM – 9:55 AM Keynote Address: Eric Hunter, PhD WEST BALLROOM 9:55 AM – 12:30 PM Antiviral Immunity Symposium WEST BALLROOM 11:00 AM – 11:30 AM Coffee Break GRAND BALLROOM PRE-FUNCTION 12:30 PM – 2:00 PM Lunch ON YOUR OWN 2:00 PM – 2:45 PM Gertrude Elion Memorial Award Lecture WEST BALLROOM 2:50 PM – 5:00 PM Hepatitis Viruses and Retroviruses WEST BALLROOM 3:30 PM – 4:00 PM Coffee Break GRAND BALLROOM PRE-FUNCTION 5:00 PM – 7:00 PM Poster Session 1 EAST BALLROOM Light hors d’oeuvres served Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 7 Schedule at a Glance Tuesday, May 23, 2017 TIME EVENT LOCATION 8:00 AM – 3:00 PM Registration GRAND BALLROOM PRE-FUNCTION 8:00 AM – 9:00 AM Continental Breakfast GRAND BALLROOM PRE-FUNCTION 9:00 AM – 9:30 AM Antonin Holý Memorial Award Lecture WEST BALLROOM 9:30 AM – 12:30 PM Emerging Viruses WEST BALLROOM 10:30 AM – 11:00 AM Coffee Break GRAND BALLROOM PRE-FUNCTION 12:30 PM – 2:00 PM New Member and First Time Attendee ROOM 204-205 Networking Light snacks served 2:00 PM – 3:00 PM Career Development Panel ROOM 203 Snacks and beverages served Wednesday, May 24, 2017 TIME EVENT LOCATION 7:30 AM – 5:00 PM Registration GRAND BALLROOM PRE-FUNCTION 7:30 AM – 8:30 AM Continental Breakfast GRAND BALLROOM PRE-FUNCTION 8:30 AM – 9:00 AM Shotgun Oral Presentations WEST BALLROOM 9:00 AM – 9:50 AM Keynote Address: Pei-Yong Shi, PhD WEST BALLROOM 9:50 AM – 12:30 PM Emerging Infections Symposium WEST BALLROOM 10:30 AM – 11:00 AM Coffee Break GRAND BALLROOM PRE-FUNCTION 12:30 PM – 1:45 PM Lunch ON YOUR OWN 1:45 PM – 2:00 PM ISAR Business Meeting WEST BALLROOM 2:00 PM – 2:30 PM William Prusoff Young Investigator Award Lecture WEST BALLROOM 2:30 PM – 3:30 PM Respiratory Viruses WEST BALLROOM 3:30 PM – 5:30 PM Poster Session 2 EAST BALLROOM Light hors d’oeuvres served 7:00 PM – 7:30 PM Closing Reception GRAND BALLROOM Light hors d’oeuvres served PRE-FUNCTION 7:30 PM – 10:00 PM Closing Banquet WEST BALLROOM Dinner served Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 8 Schedule at a Glance Thursday, May 25, 2017 TIME EVENT LOCATION 8:00 AM – 12:00 PM Registration GRAND BALLROOM PRE-FUNCTION 8:00 AM – 9:00 AM Continental Breakfast GRAND BALLROOM PRE-FUNCTION 9:00 AM – 10:30 AM Medicinal Chemistry WEST BALLROOM 10:30 AM – 11:00 AM Coffee Break GRAND BALLROOM PRE-FUNCTION 11:00 AM – 12:30 PM DNA Viruses and Respiratory Viruses WEST BALLROOM 12:30 PM Conference Concludes Program and Abstracts of the 30th International Conference on Antiviral Research (ICAR) 9 2017 ISAR Award Winners Gertrude Elion Memorial Lecture Award Michael J. Sofia, PhD Mike Sofia is the principle inventor of sofosbuvir (Sovaldi and Harvoni), the first curative treatment for chronic hepatitis C . He is Chief Scientific Officer of Arbutus Biopharma, a company focused on the discovery and development of curative therapies for hepatitis B . He is listed on more than 50 US patents and on numerous patent applications, and has authored over 100 research papers and 12 book chapters . He holds a professorship at the Baruch S . Blumberg Institute in Doylestown, PA and is an adjunct professor at Drexel University School of Medicine in Philadelphia . Mike earned a BA degree in chemistry from Cornell University in 1980 and received his PhD in organic chemistry from the University of Illinois, Urbana-Champaign in 1984 . He did his postdoctoral training in synthetic organic chemistry as an NIH fellow at Columbia University . During his early career in the pharmaceutical industry, he held the position of Group Director for New Leads Chemistry at Bristol- Myers Squibb, Vice President of Research at Intercardia Research Labs and research positions of increasing responsibility at Eli Lilly and at the Squibb Institute for Medical Research . He then moved to Pharmasset and was senior vice president for chemistry until its acquisition by Gilead in 2012 . He then co-founded OnCore Biopharma, which merged with Tekmira in 2015 to form Arbutus . In addition to his “day job,” Mike is a member of the editorial advisory boards of several scientific journals, the Board of the Blumberg Institute and the Board of Trustees of the University of the Sciences in Philadelphia . He was the recipient of Pennsylvania Bio’s 2014 Scientific Achievement Award, the 2015 Heroes of Chemistry Award of the American Chemical Society and the 2016 IUPAC-Richter Prize . Together with Charlie Rice and Ralf Bartenschlager, he received the 2016 Lasker-Debakey Award in Clinical Medical Research for his contributions to the discovery of a cure for hepatitis C .
Load more

Recommended publications
  • Aicuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
    AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults Wuppertal, August 01, 2017 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the Company has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised adults. Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner. Oral pritelivir, a small molecule helicase-primase inhibitor with a novel mode of action, is currently in a clinical phase 2 study, called PRIOH-1, in the U.S. to evaluate the product candidate’s efficacy and safety compared to i.v. foscarnet, a virostatic agent which is used mainly for the treatment of herpes viruses resistant to other antiviral drugs. In a prior phase 2 study, oral pritelivir showed to significantly improve the suppression of viral shedding compared to the current standard of care for genital HSV-2 infections, the nucleoside analog valacyclovir. The results of this study were published in the Journal of the American Medical Association (JAMA) earlier this year. “The decision by the FDA to grant fast track designation to oral pritelivir underscores that our product might fill the major need for innovative, more efficacious therapies for immunocompromised patients with HSV infections that have become resistant to standard treatments,” said Dr.
    [Show full text]
  • Herpes Simplex Virus
    HSV Herpes simplex virus HSV (Herpes simplex virus) can be spread when an infected person is producing and shedding the virus. Herpes simplex can be spread through contact with saliva, such as sharing drinks. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with ascab characteristic of herpetic disease. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. www.MedChemExpress.com 1 HSV Inhibitors (Z)-Capsaicin 1-Docosanol (Zucapsaicin; Civamide; cis-Capsaicin) Cat. No.: HY-B1583 (Behenyl alcohol) Cat. No.: HY-B0222 (Z)-Capsaicin is the cis isomer of capsaicin, acts 1-Docosanol is a saturated fatty alcohol used as an orally active TRPV1 agonist, and is used in traditionally as an emollient, emulsifier, and the research of neuropathic pain. thickener in cosmetics, and nutritional supplement; inhibitor of lipid-enveloped viruses including herpes simplex. Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 500 mg 2-Deoxy-D-glucose 20(R)-Ginsenoside Rh2 (2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose) Cat. No.: HY-13966 Cat. No.: HY-N1401 2-Deoxy-D-glucose is a glucose analog that acts as 20(R)-Ginsenoside Rh2, a matrix a competitive inhibitor of glucose metabolism, metalloproteinase (MMP) inhibitor, acts as a inhibiting glycolysis via its actions on hexokinase.
    [Show full text]
  • An in Silico Study of the Ligand Binding to Human Cytochrome P450 2D6
    AN IN SILICO STUDY OF THE LIGAND BINDING TO HUMAN CYTOCHROME P450 2D6 Sui-Lin Mo (Doctor of Philosophy) Discipline of Chinese Medicine School of Health Sciences RMIT University, Victoria, Australia January 2011 i Declaration I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at RMIT university or any other educational institution, except where due acknowledgment is made in the thesis. Any contribution made to the research by others, with whom I have worked at RMIT university or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project‘s design and conception or in style, presentation and linguistic expression is acknowledged. PhD Candidate: Sui-Lin Mo Date: January 2011 ii Acknowledgements I would like to take this opportunity to express my gratitude to my supervisor, Professor Shu-Feng Zhou, for his excellent supervision. I thank him for his kindness, encouragement, patience, enthusiasm, ideas, and comments and for the opportunity that he has given me. I thank my co-supervisor, A/Prof. Chun-Guang Li, for his valuable support, suggestions, comments, which have contributed towards the success of this thesis. I express my great respect to Prof. Min Huang, Dean of School of Pharmaceutical Sciences at Sun Yat-sen University in P.R.China, for his valuable support.
    [Show full text]
  • Review Article Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy
    Hindawi Publishing Corporation Neural Plasticity Volume 2016, Article ID 1320423, 18 pages http://dx.doi.org/10.1155/2016/1320423 Review Article Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy James Ahn,1 Hyung Seok Ahn,2 Jae Hoon Cheong,3 and Ike dela Peña1 1 Department of Pharmaceutical and Administrative Sciences, Loma Linda University, Loma Linda, CA 92350, USA 2School of Medicine, Chungnam National University, Daejeon 301-747, Republic of Korea 3Department of Pharmacy, Sahmyook University, Seoul 139-742, Republic of Korea Correspondence should be addressed to Ike dela Pena;˜ [email protected] Received 9 November 2015; Revised 30 December 2015; Accepted 10 January 2016 Academic Editor: Daniel Fung Copyright © 2016 James Ahn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Typical treatment plans for attention-deficit/hyperactivity disorder (ADHD) utilize nonpharmacological (behavioral/psychosocial) and/or pharmacological interventions. Limited accessibility to behavioral therapies and concerns over adverse effects of pharmacological treatments prompted research for alternative ADHD therapies such as natural product-derived treatments and nutritional supplements. In this study, we reviewed the herbal preparations and nutritional supplements evaluated in clinical studies as potential ADHD treatments and discussed their performance with regard to safety and efficacy in clinical trials. We also discussed some evidence suggesting that adjunct treatment of these agents (with another botanical agent or pharmacological ADHD treatments) may be a promising approach to treat ADHD.
    [Show full text]
  • List of Action Films of the 2010S - Wikipedia, the Free Encyclopedia
    List of action films of the 2010s - Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/List_of_action_films_of_the_2010s List of action films of the 2010s From Wikipedia, the free encyclopedia This is an incomplete list, which may never be able to satisfy particular standards for completeness. You can help by expanding it (//en.wikipedia.org /w/index.php?title=List_of_action_films_of_the_2010s&action=edit) with reliably sourced entries. This is chronological list of action films originally released in the 2010s. Often there may be considerable overlap particularly between action and other genres (including, horror, comedy, and science fiction films); the list should attempt to document films which are more closely related to action, even if it bends genres. Title Director Cast Country Sub-Genre/Notes 2010 13 Assassins Takashi Miike Koji Yakusho, Takayuki Yamada, Yusuke Iseya Martial Arts[1] 14 Blades Daniel Lee Donnie Yen, Vicky Zhao, Wu Chun Martial Arts[2] The A-Team Joe Carnahan Liam Neeson, Bradley Cooper, Quinton Jackson [3] Alien vs Ninja Seiji Chiba Masanori Mimoto, Mika Hijii, Shuji Kashiwabara [4][5] Bad Blood Dennis Law Simon Yam, Bernice Liu, Andy On [6] Sorapong Chatree, Supaksorn Chaimongkol, Kiattisak Bangkok Knockout Panna Rittikrai, Morakot Kaewthanee [7] Udomnak Blades of Blood Lee Joon-ik Cha Seung-won, Hwang Jung-min, Baek Sung-hyun [8] The Book of Eli Albert Hughes, Allen Hughes Denzel Washington, Gary Oldman, Mila Kunis [9] The Bounty Hunter Andy Tennant Jennifer Aniston, Gerard Butler, Giovanni Perez Action comedy[10] The Butcher, the Chef and the Wuershan Masanobu Ando, Kitty Zhang, You Benchang [11] Swordsman Centurion Neil Marshall Michael Fassbender, Olga Kurylenko, Dominic West [12] City Under Siege Benny Chan [13] The Crazies Breck Eisner Timothy Olyphant, Radha Mitchell, Danielle Panabaker Action thriller[14] Date Night Shawn Levy Steve Carell, Tina Fey, Mark Wahlberg Action comedy[15] The Expendables Sylvester Stallone Sylvester Stallone, Jason Statham, Jet Li [16] Faster George Tillman, Jr.
    [Show full text]
  • Review Article Natural Compounds for the Management of Parkinson's
    Hindawi BioMed Research International Volume 2018, Article ID 4067597, 12 pages https://doi.org/10.1155/2018/4067597 Review Article Natural Compounds for the Management of Parkinson’s Disease and Attention-Deficit/Hyperactivity Disorder Juan Carlos Corona Laboratory of Neurosciences, Hospital Infantil de Mexico´ Federico Gomez,´ Mexico Correspondence should be addressed to Juan Carlos Corona; [email protected] Received 28 June 2018; Revised 31 October 2018; Accepted 11 November 2018; Published 22 November 2018 Guest Editor: Francesco Facchiano Copyright © 2018 Juan Carlos Corona. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Parkinson’s disease (PD) is the second most common neurodegenerative disorder with an unknown aetiology. Te pathogenic mechanisms include oxidative stress, mitochondrial dysfunction, protein dysfunction, infammation, autophagy, apoptosis, and abnormal deposition of �-synuclein. Currently, the existing pharmacological treatments for PD cannot improve fundamentally the degenerative process of dopaminergic neurons and have numerous side efects. On the other hand, attention-defcit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder of childhood and is characterised by hyperactivity, impulsiv- ity, and inattention. Te aetiology of ADHD remains unknown, although it has been suggested that its pathophysiology involves abnormalities in several brain regions, disturbances of the catecholaminergic pathway, and oxidative stress. Psychostimulants and nonpsychostimulants are the drugs prescribed for the treatment of ADHD; however, they have been associated with increased risk of substance use and have several side efects. Today, there are very few tools available to prevent or to counteract the progression of such neurological disorders.
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]
  • Analytical Reference Standards
    Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation.
    [Show full text]
  • Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2
    viruses Review Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2 Lauren A. Sadowski 1,†, Rista Upadhyay 1,2,†, Zachary W. Greeley 1,‡ and Barry J. Margulies 1,3,* 1 Towson University Herpes Virus Lab, Department of Biological Sciences, Towson University, Towson, MD 21252, USA; [email protected] (L.A.S.); [email protected] (R.U.); [email protected] (Z.W.G.) 2 Towson University Department of Chemistry, Towson, MD 21252, USA 3 Molecular Biology, Biochemistry, and Bioinformatics Program, Towson University, Towson, MD 21252, USA * Correspondence: [email protected] † Authors contributed equally to this manuscript. ‡ Current address: Becton-Dickinson, Sparks, MD 21152, USA. Abstract: Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaher- pesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses. Keywords: acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfi- navir; HSV-1; HSV-2 Citation: Sadowski, L.A.; Upadhyay, R.; Greeley, Z.W.; Margulies, B.J. Current Drugs to Treat Infections 1. Introduction with Herpes Simplex Viruses-1 and -2. The world of anti-herpes simplex (anti-HSV) agents took flight in 1962 with the FDA Viruses 2021, 13, 1228.
    [Show full text]
  • Comparative Studies on Behavioral, Cognitive and Biomolecular Profiling of ICR, C57BL/6 and Its Sub-Strains Suitable for Scopolamine-Induced Amnesic Models
    Article Comparative Studies on Behavioral, Cognitive and Biomolecular Profiling of ICR, C57BL/6 and Its Sub-Strains Suitable for Scopolamine-Induced Amnesic Models Govindarajan Karthivashan 1, Shin-Young Park 1, Joon-Soo Kim 1, Duk-Yeon Cho 1, Palanivel Ganesan 1,2 and Dong-Kug Choi 1,2,* 1 Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea; [email protected] (G.K.); [email protected] (S.-Y.P.); [email protected] (J.-S.K.); [email protected] (D.-Y.C.); [email protected] (P.G.) 2 Nanotechnology Research Center, Department of Applied Life Science, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea * Correspondence: [email protected]; Tel.: +82-43-840-3610 Received: 5 July 2017; Accepted: 1 August 2017; Published: 9 August 2017 Abstract: Cognitive impairment and behavioral disparities are the distinctive baseline features to investigate in most animal models of neurodegenerative disease. However, neuronal complications are multifactorial and demand a suitable animal model to investigate their underlying basal mechanisms. By contrast, the numerous existing neurodegenerative studies have utilized various animal strains, leading to factual disparity. Choosing an optimal mouse strain for preliminary assessment of neuronal complications is therefore imperative. In this study, we systematically compared the behavioral, cognitive, cholinergic, and inflammatory impairments of outbred ICR and inbred C57BL/6 mice strains subject to scopolamine-induced amnesia. We then extended this study to the sub-strains C57BL/6N and C57BL/6J, where in addition to the above-mentioned parameters, their endogenous antioxidant levels and cAMP response-element binding protein (CREB)/brain- derived neurotrophic factor (BDNF) protein expression were also evaluated.
    [Show full text]
  • Multiple Causality of Differences in Taboo Translation of Blockbuster Films by Chinese Fansubbers and Professionals
    Multiple Causality of Differences in Taboo Translation of Blockbuster Films by Chinese Fansubbers and Professionals Zhengguo He Thesis submitted in fulfilment of the regulations for the degree of Doctor of Philosophy Newcastle University School of Modern Languages June 2018 Acknowledgement This thesis owes its existence to the expert supervision and encouragement of my first supervisor, Dr Ya-yun Chen, who always inspired me with her insightful feedback, and my second supervisor, Dr Valerie Pellatt, whose rigorous and holistic academic thinking had a profound influence on the structure of my thesis. It has been both a privilege and a pleasure to have the opportunity to be supervised by two supportive and inspiring scholars. I am also indebted to my Annual Panel Reviewers Professor Qian Jun, Dr Michael Jin, and Dr Francis Jones for their insightful review and advice. I would also like to express my deep gratitude to my viva examiners Drs Yvonne Lee and Pauline Henry-Tierney, for their very detailed and valuable critique. My sincere thanks must go to my family and friends during my PhD studies. Special thanks should be given to my family, especially my father, Qingxiang He, for his unfailing support throughout my years in the UK and Dr Mark James for his moral support and encouragement. I would also like to extend my sincere gratitude to Dr Joseph Banks and Karen Blacker, who offered me advice regarding my English composition; and Drs Peter Avery and Damien Hall for their valuable comments on my statistical analysis. i Note on Translation and Transliteration All translations from Chinese in this thesis are mine, unless otherwise noted.
    [Show full text]
  • Alzheimer's Disease 2
    J Chin Med 16(2-3): 63-87, 2005 63 PATHOGENESIS OF NEURODEGENERATIVE DISEASES AND THE EFFECT OF NATURAL PRODUCTS ON NITRIC OXIDE PRODUCTION IMPLICATING IN THESE DISEASES Yuh-Chiang Shen1†, Young-Ji Shiao1†, Yen-Jen Sung2 and Chuen-Neu Wang1 1National Research Institute of Chinese Medicine, Taipei, Taiwan 2Institute of Anatomy and Cell Biology, School of Medicine, National Yang-Ming University, Taipei, Taiwan (Received 11th April 2005, accepted 2nd August 2005) Nitric oxide (NO) is a free radical synthesized from L-arginine by three isoforms of NO synthase (NOS). NO is involved in a wide range of physiological functions. It functions as neurotransmitter by modulating the release of glutamate and the neurotransmission of N-methyl- D-aspartate (NMDA) receptor, as neuro-endothelial-derived relaxing factor through the action on guanylyl cyclase (sGC), and as inflammatory molecule in response to proinflammatory cytokines or bacterial endotoxin. NO is also implicated in multiple pathological conditions such as acute and chronic neurodegeneration. In spite of the different mechanisms of pathogenesis for these neurodegenerative diseases, NO may play a pivotal role in the pathological conditions of these diseases. Under pathological conditions, NO is produced either from activated neuronal NOS (nNOS) in neuron or inducible NOS (iNOS) in glial cells by increased intracellular calcium concentration through glutamate-NMDA receptor interaction or by inflammatory cytokine- mediated signaling pathway, respectively. NO and its toxic metabolite peroxynitrite (ONOO−) directly injure membrane integrity or impair mitochondrial function leading to DNA break, lipid peroxidation, and protein nitrosylation. These events consequently activate caspase-cascade or poly-(ADP-ribose) polymerase 1 (PARP) resulting in apoptotic or necrotic cell death.
    [Show full text]